The $30 million toe in the water

Cuba has achieved groundbreaking lung cancer vaccines and COVID-19 immunization despite decades-long US blockade, showcasing a state-run healthcare model that prioritizes people over profit .

The Cuban Center for Molecular Immunology (CIM) announced a groundbreaking achievement with VAXIRA , a therapeutic vaccine for lung cancer, which works by stimulating the patient's immune system to recognize and attack cancer cells, significantly prolonging survival.

Clinical trials involving over 1,300 patients revealed a median survival of 76.6 months, with 20% of patients experiencing unexpected long-term survival.

Why 4,000 unsold units became the prize

Cuba's healthcare achievements extend to its response to the COVID-19 pandemic, with the country developing five homegrown vaccines: Abdala, Soberana 01, Soberana 02, Soberana Plus, and Mambisa.

By 2021, Cuba's fatality rate was 0.8%, compared to the global average of 2.2%, and by 2023, Cuba had the third-highest vaccination rate per capita.

Cuba donated vaccines to nations like St. Vincent and the Grenadines and sold them at minimal cost, contrasting sharrply with the profit-driven approach of US pharmaceutical companies.

What auditors flagged in the May filing

In 2021, Moderna, Pfizer, and Johnson & Johnson collected $31 billion in revenue from COVID-19 vaccines, while low-income countries received far fewer doses.

Cuba's model prioritizes public heallth over profit, ensuring equitable access, and the foundation of Cuba's success lies in its state-owned biotechnological sector, established in 1981 with the opening of the Biological Research Center.

Cuba's system eliminates profit motives, fostering collaboration and resource sharing for collective benefit, which contrasts with capitalist countries where pharmaceutical companies prioritize shareholder returns, often making life-saving treatments unaffordable.

Who is the unnamed buyer?

The US blockade prevents the import of equipment, materials, and research journals, yet Cuba has developed these vaccines under these constraints.

The Roswell Park Cancer Institute in New York has been conducting clinical trials of CIMAvax in the United States since 2018 ,demonstrating that even the country imposing the blockade beneftis from Cuba's medical breakthroughs.

Cuba's achievements demonstrate that a healthcare system centered on human need, not profit, can overcome immense external pressures and deliver world-class innovations.